SARS-CoV-2 Infection: What Is Currently Known about Homocysteine Involvement?
Nina FilipElena CojocaruOana Viola BadulescuAndreea ClimAlin Constantin PinzariuGabriela BordeianuAlina Elena JehacCristina Elena IancuCristiana FilipMinela Aida MărănducăIvona Andreea SovaIonela Lacramioara SerbanPublished in: Diagnostics (Basel, Switzerland) (2022)
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout the world causing health, social and economic instability. The severity and prognosis of patients with SARS-CoV-2 infection are associated with the presence of comorbidities such as cardiovascular disease, hypertension, chronic lung disease, cerebrovascular disease, diabetes, chronic kidney disease, and malignancy. Thrombosis is one of the most serious complications that can occur in patients with COVID-19. Homocysteine is a non-proteinogenic α-amino acid considered a potential marker of thrombotic diseases. Our review aims to provide an updated analysis of the data on the involvement of homocysteine in COVID-19 to highlight the correlation of this amino acid with disease severity and the possible mechanisms by which it intervenes.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- amino acid
- cardiovascular disease
- coronavirus disease
- chronic kidney disease
- healthcare
- type diabetes
- mental health
- blood pressure
- public health
- end stage renal disease
- pulmonary embolism
- risk factors
- human health
- cardiovascular events
- big data
- glycemic control
- health information
- metabolic syndrome
- adipose tissue
- health promotion
- climate change
- coronary artery disease
- peritoneal dialysis
- insulin resistance
- artificial intelligence